News | In The News | Publications
September 29, 2014
Galeterone in Four Castrate Resistant Prostate Cancer (CRPC) Populations: Results from ARMOR2. Taplin, M-E., et al. European Society for Medical Oncology (ESMO) 2014 Congress.
May 31, 2014
Galeterone in men with CRPC: Results in Four Distinct Patient Populations from the ARMOR2 Study. Montgomery, R., et al. 2014 American Society of Clinical Oncology (ASCO), Abstract #5029.
January 30, 2014
ARMOR2: Galeterone in Progressive CRPC Patients Who Have Failed Primary Therapy. Taplin, M, et al. 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Abstract #71.
October 22, 2013
Galeterone Suppresses Castration-Resistant and Enzalutamide-Resistant Prostate Cancer Growth in Vitro. Al Nakouzi, N, et al. AACR-NCI-EORTC 2013 International Conference on Molecular Targets and Cancer Therapeutics, Abstract #C89.
May 15, 2013
Comparison of the pharmacokinetics (PK) of galeterone novel oral formulations. Kramer, W, et al. 2013 American Society of Clinical Oncology (ASCO), Abstract #e16075 (publication-only).
February 15, 2013
Galeterone, Abiraterone, Orteronel and Ketoconazole Exhibit Differential Inhibitory Effects on CYP17 and Steroidogenesis. Jacoby, D. and Williams, M. 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Abstract #184.
June 3, 2012
Phase 1 clinical trial of galeterone (TOK-001) a multifunctional antiandrogen and CYP17 inhibitor in Castration Resistant Prostate Cancer (CRPC). Montgomery B, et al. 2012 Annual Meeting of the American Society of Clinical Oncology, Abstract 4665
April 3, 2012
ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration-resistant prostate cancer (CRPC). Taplin M, et al. American Association for Cancer Research Annual Meeting 2012, Abstract CT-07.
